Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.
The mutation rate of the Omicron sublineage has led to baseline resistance against all
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA. 2 and BA. 5 subvariant predominance: A systematic literature …
M Drysdale, M Berktas, DC Gibbons, C Rolland… - Infection, 2024 - Springer
Purpose To evaluate clinical outcomes associated with sotrovimab use during Omicron BA.
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
2 and BA. 5 predominance. Methods Electronic databases were searched for observational …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort …
M Drysdale, H Tibble, V Patel, DC Gibbons… - BMC Infectious …, 2024 - Springer
Background The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against
new circulating variants remains unclear. We sought to describe characteristics and clinical …
new circulating variants remains unclear. We sought to describe characteristics and clinical …
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study
M Drysdale, ER Galimov… - BMJ Open …, 2024 - bmjopenrespres.bmj.com
Background We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in
highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective …
highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective …
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
CF Bell, P Bobbili, R Desai, DC Gibbons… - Clinical Drug …, 2024 - Springer
Abstract Background and Objective The coronavirus disease 2019 (COVID-19) pandemic
has been an unprecedented healthcare crisis, one that threatened to overwhelm health …
has been an unprecedented healthcare crisis, one that threatened to overwhelm health …
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
D Focosi - 2024 - Springer
Monoclonal antibodies targeting the Spike protein of SARS-CoV-2 have been widely
deployed in the ongoing COVID-19 pandemic. I review here the impact of those therapeutics …
deployed in the ongoing COVID-19 pandemic. I review here the impact of those therapeutics …
日本人SARS-CoV-2 感染症患者を対象とした実臨床下でのソトロビマブの安全性及び有効性の評価―一般使用成績調査の最終報告―
野瀬靖代， 檀上卓馬， 溝端宏子， 金内明美， 小田憲司… - 感染症学雑誌, 2025 - jstage.jst.go.jp
抄録 日本における実臨床下でのソトロビマブ (本剤) の安全性及び有効性を明らかにするための
一般使用成績調査を実施した. 新型コロナウイルス (SARS-CoV-2) 感染症の重症化リスク因子を …
一般使用成績調査を実施した. 新型コロナウイルス (SARS-CoV-2) 感染症の重症化リスク因子を …